Recombinant monoclonal antibody to Human EGFR. Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
Host: Human
Isotype: IgG2 - kappa
Applications: ELISA, IP, FC, FuncS, Neut, IF, ICC
Figure 1 EGFR G465R mutant reveals almost complete abrogation of panitumumab and cetuximab binding.
EGFR mutation G465R abrogates binding of panitumumab and cetuximab at the protein level. Wile-type and mutant EGFR-Fc proteins were expressed and the binding of therapeutic antibodies to immobilized proteins was assessed by ELISA. Data are means from 3 experiments +/- SEM. * p<0.05, ** p<0.01, n.s. = not significant (student's T-test comparing binding of respective antibody to mutant versus wt EGFR-Fc).
Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., ... & Engel, E. (2015). Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget, 6(14), 12035.
Figure 2 EGFR G465R mutant reveals almost complete abrogation of panitumumab and cetuximab binding.
Panitumumab and cetuximab binding is abrogated in CHO cells transfected with EGFR G465R . EGFR negative CHO cells were transfected with wild type EGFR or mutants thereof. Binding of panitumumab, cetuximab or a control polyclonal EGFR antibody was assessed by FACS analysis 48h after transfection. FSC = forward scatter.
Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., ... & Engel, E. (2015). Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget, 6(14), 12035.
Figure 3 EGFR G465R mutation induces cross-resistance to panitumumab and cetuximab in an EGF-dependent Ba/ F3 cellular model.
A: EGFR signaling in EGF-dependent Ba/F3 model. Wt and S492R or G465R mutant EGFR-expressing Ba/F3 cells were cultured in the presence or absence of EGF and with addition of cetuximab, panitumumab, rituximab or erlotinib. After 2 hours, cells were harvested and EGFR/pEGFR expression analyzed by western blot analysis. B: Sensitivity of EGFR wt or EGFR G465R mutant- transfected Ba/F3 cells to treatment with EGFR-targeted antibodies. Ba/F3 cells were transformed to IL-3 independence with EGFR wt or mutant constructs and subsequently cultured in the presence or absence of EGF or with EGF in combination with panitumumab, cetuximab or control antibody rituximab. The number of viable cells was determined by trypan blue exclusion every 12 hours beginning 24 hours after seeding and plotted. Data are means from triplicate experiments +/-SEM.
Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., ... & Engel, E. (2015). Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget, 6(14), 12035.
Figure 4 In vitro EGFR targeting of panitumumab.
Immunofluorescence staining of UM-SCC-22B tumor cells and tissues for EGFR using panitumumab as the primary antibody.
Liu, Z., Liu, Y., Jia, B., Zhao, H., Jin, X., Li, F., ... & Wang, F. (2010). Epidermal growth factor receptor–targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Molecular cancer therapeutics, 1535-7163.
Figure 5 In vitro EGFR targeting of panitumumab.
In vitro inhibition of 125I-panitumumab binding to EGFR on UM-SCC-22B human head and neck cancer cells by DOTA-panitumumab and panitumumab. Points, mean (n = 3); bars, SD.
Liu, Z., Liu, Y., Jia, B., Zhao, H., Jin, X., Li, F., ... & Wang, F. (2010). Epidermal growth factor receptor–targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Molecular cancer therapeutics, 1535-7163.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-EGFR ADCC Recombinant Antibody (Panitumumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human EGFR. Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
CAT | Product Name | Application | Type |
PFBL-080 | Human Anti-EGFR Recombinant Antibody; Fab Fragment (PFBL-080) | ELISA, WB, FuncS | Human Fab |
PFBZ-039 | Mouse Anti-EGFR Recombinant Antibody (clone mAb528); Fab Fragment | FC | Mouse Fab |
PFBW-039 | Human Anti-EGFR Recombinant Antibody (clone Cetuximab (IMC-C225)); Fab Fragment | FuncS | Chimeric (mouse/human) Fab |
PFBC-040 | Human Anti-EGFR Recombinant Antibody (clone MR1); Fab Fragment | Block | Human Fab |
PFBL-459 | Human Anti-EGFR Recombinant Antibody (clone C225); Fab Fragment | FC | Human Fab |
CAT | Product Name | Application | Type |
PNBL-016 | Recombinant Anti-Human EGFR VHH Single Domain Antibody (7D12) | WB, ELISA | Llama VHH |
PNBL-017 | Recombinant Anti-Human EGFR VHH Single Domain Antibody (9G8) | FuncS, ELISA, IF | Llama VHH |
PNBL-018 | Recombinant Anti-Human EGFR VHH Single Domain Antibody (EgA1) | FuncS, SPR | Llama VHH |
HPAB-AP881-YC | Recombinant Llama Anti-EGFR Single Domain Antibody (VHH122) | ELISA, FC, IP, FuncS | Llama VHH |
HPAB-AP882-YC | Recombinant Llama Anti-EGFR Single Domain Antibody (VHH205) | ELISA | Llama VHH |
CAT | Product Name | Application | Type |
PFBW-088 | Mouse Anti-EGFR Recombinant Antibody (clone 7A7); Fab Fragment | ELISA, WB | Mouse Fab |
FAMAB-0202-CN | Human Anti-EGFR Recombinant Antibody (clone E10) | ELISA, WB | Human IgG |
HPAB-0727-CN | Mouse Anti-EGFR Recombinant Antibody (clone EGFR) | ELISA, FC, IHC, Neut | Mouse IgG1, κ |
HPAB-0060-WJ | Human Anti-EGFR Recombinant Antibody (HPAB-0060-WJ) | ELISA, RIA, FC | Human IgG1, κ |
HPAB-0136-YJ | Human Anti-EGFR Recombinant Antibody (HPAB-0136-YJ) | ELISA, FC, Inhib, FuncS | Human IgG1 |
CAT | Product Name | Application | Type |
TAB-270MZ | Human Anti-EGFR Recombinant Antibody (TAB-270MZ) | ELISA | Human antibody |
PABX-053 | Recombinant Human Anti-EGFR Antibody (DL11) | WB, ELISA, FuncS | IgG |
PABX-052-S (P) | Recombinant Human Anti-EGFR Antibody scFv Fragment (Nimotuzumab) | WB, ELISA, FuncS | scFv |
PABX-053-S (P) | Recombinant Human Anti-EGFR Antibody scFv Fragment (DL11) | WB, ELISA, FuncS | scFv |
PABX-053-F (E) | Recombinant Human Anti-EGFR Antibody Fab Fragment (DL11) | WB, ELISA, FuncS | Fab |
CAT | Product Name | Application | Type |
TAB-272MZ | Human Anti-EGFR Recombinant Antibody (TAB-272MZ) | FuncS | Chimeric (mouse/human) IgG |
TAB-302MZ | Human Anti-EGFR Recombinant Antibody (TAB-302MZ) | ELISA | Chimeric (mouse/human) IgG1 |
TAB-272MZ-S(P) | Mouse Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-272MZ-S(P)) | FuncS | Mouse scFv |
TAB-302MZ-S(P) | Mouse Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-302MZ-S(P)) | ELISA | Mouse scFv |
TAB-302MZ-F(E) | Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-302MZ-F(E)) | ELISA | Chimeric (mouse/human) Fab |
CAT | Product Name | Application | Type |
TAB-274MZ | Human Anti-EGFR Recombinant Antibody (TAB-274MZ) | FC | Humanized IgG |
TAB-297MZ | Anti-Human EGFR Recombinant Antibody (H225) | ELISA, WB | Humanized antibody |
TAB-298MZ | Anti-Human EGFR Recombinant Antibody (Hu225) | ELISA, WB | Humanized antibody |
TAB-274MZ-S(P) | Human Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-274MZ-S(P)) | FC | Humanized scFv |
TAB-274MZ-F(E) | Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-274MZ-F(E)) | FC | Humanized Fab |
CAT | Product Name | Application | Type |
TAB-310MZ | Mouse Anti-EGFR Recombinant Antibody (TAB-310MZ) | ELISA, FuncS | Mouse IgG |
TAB-311MZ | Mouse Anti-EGFR Recombinant Antibody (TAB-311MZ) | ELISA, FuncS | Mouse IgG |
TAB-312MZ | Mouse Anti-EGFR Recombinant Antibody (TAB-312MZ) | ELISA, FuncS | Mouse IgG |
TAB-316MZ | Anti-Human EGFR Recombinant Antibody (07D06) | FuncS, Inhib | |
TAB-317MZ | Anti-Human EGFR Recombinant Antibody (12D03) | FuncS, Inhib |
CAT | Product Name | Application | Type |
Gly-055LC | Recombinant Anti-Human EGFR Antibody (Fc glycosylation/High-mannose glycosylated) | ELISA | Chimeric antibody (mouse/human) |
Gly-144LC | Recombinant Anti-Human EGFR Antibody (Fc glycosylation) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
Gly-055LC-1 | Recombinant Anti-Human EGFR Antibody (Fc glycosylation/High-mannose glycosylated) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
Gly-167LC | Recombinant Anti-Human EGFR Antibody (Non-glycosylated) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
BRD-0183MZ | Chicken Anti-EGFR Polyclonal IgY | WB | Chicken antibody |
BRD-0668MZ | Chicken Anti-EGFR Polyclonal IgY | WB | Chicken antibody |
CAT | Product Name | Application | Type |
MHC-LC773 | A*0201/Human EGFR (YLNTVQPTCV) MHC Tetramer | FCM | |
MHC-LC4545 | PE-DQB1*03:02/Human EGFR (SRALEEKKGNYVVTHG) MHC Tetramer | FCM | |
MHC-YF409 | A*02:01/Human EGF-R-479 (KLFGTSGQKT) MHC Pentamer | FCM |
CAT | Product Name | Application | Type |
NEUT-722CQ | Rabbit Anti-EGFR Recombinant Antibody (clone CBL1011) | Neut | Rabbit IgG |
NEUT-723CQ | Mouse Anti-EGFR Recombinant Antibody (clone CBL931) | WB, IP, IHC, ICC, Neut | Mouse IgG1 |
NEUT-724CQ | Rabbit Anti-EGFR Recombinant Antibody (clone D1D4J) | IF, FC, WB, IP, Neut | Rabbit IgG |
CAT | Product Name | Application | Type |
MOR-1101 | Hi-Affi™ Rabbit Anti-EGFR Recombinant Antibody (clone DS1101AB) | IHC-P | Rabbit IgG |
MOR-4520 | Hi-Affi™ Rabbit Anti-EGFR Recombinant Antibody (clone TH28DS) | IF, ICC, FC | Rabbit IgG |
MOR-4675 | Hi-Affi™ Rabbit Anti-EGFR Recombinant Antibody (clone TH189DS) | WB, IF, ICC, FC | Rabbit IgG |
MOR-4676 | Hi-Affi™ Rabbit Anti-EGFR Recombinant Antibody (clone TH190DS) | WB, IF, ICC, FC | Rabbit IgG |
MOR-0033-FY | Rabbit Anti-EGFR Recombinant Antibody (clone AFY0004) | ICC, IHC, WB | Rabbit IgG |
CAT | Product Name | Application | Type |
AFC-TAB-165 | Afuco™ Anti-EGFR ADCC Recombinant Antibody (Matuzumab), ADCC Enhanced | Neut, ELISA, IF, IP, FuncS, FC | ADCC enhanced antibody |
AFC-TAB-464CQ | Afuco™ Anti-EGFR ADCC Recombinant Antibody (Tomuzotuximab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, FuncS | ADCC enhanced antibody |
AFC-TAB-003 | Afuco™ Anti-EGFR ADCC Recombinant Antibody (Cetuximab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-040 | Afuco™ Anti-EGFR ADCC Recombinant Antibody (Zalutumumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
AFC-TAB-119 | Afuco™ Anti-EGFR ADCC Recombinant Antibody (Necitumumab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | ADCC enhanced antibody |
CAT | Product Name | Application | Type |
HPAB-AP637-YC-S(P) | Human Anti-EGFR Recombinant Antibody (clone EGL2); scFv Fragment | ELISA, FC, IF, Inhib | Human scFv |
HPAB-S0022-YC-S(P) | Human Anti-EGFR Recombinant Antibody (clone E7.6.3); scFv Fragment | ELISA, Inhib, FuncS | Human scFv |
PSBS-0060 | Human Anti-EGFR Recombinant Antibody (Clone FM318); scFv Fragment | ELISA, IB, FuncS | Human scFv |
PSBS-0061 | Human Anti-EGFR Recombinant Antibody (Clone FM329); scFv Fragment | ELISA, FuncS | Human scFv |
HPAB-2098-FY-S(P) | Mouse Anti-EGFR Recombinant Antibody (clone Mint5); scFv Fragment | ICC, Inhib | Mouse scFv |
Submit a review or a question
There are currently no Customer reviews or questions for TAB-020. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.